CEA Response and Depth of Response (DpR) to Predict Clinical Outcomes of First-Line Cetuximab Treatment for Metastatic Colorectal Cancer

Yu Sunakawa,Akihito Tsuji,Tadamichi Denda,Y. Segawa,Yuji Negoro,Ken Shimada,Mitsugu Kochi,Masato Nakamura,Masahito Kotaka,Hiroaki Tanioka,Akinori Takagane,Satoshi Tani,Tatsuro Yamaguchi,Takanori Watanabe,Masahiro Takeuchi,Masashi Fujii,Wataru Ichikawa

CEA Response and Depth of Response (DpR) to Predict Clinical Outcomes of First-Line Cetuximab Treatment for Metastatic Colorectal Cancer

2017

Yu Sunakawa
Akihito Tsuji
Tadamichi Denda
Y. Segawa
Yuji Negoro
Ken Shimada
Mitsugu Kochi
Masato Nakamura
Masahito Kotaka
Hiroaki Tanioka
Akinori Takagane
Satoshi Tani
Tatsuro Yamaguchi
Takanori Watanabe
Masahiro Takeuchi
Masashi Fujii
Wataru Ichikawa

Background The decrease in carcinoembryonic antigen (CEA) level is faster and greater during cetuximab treatment than bevacizumab treatment and correlates with prolonged survival in patients with metastatic colorectal cancer (mCRC) who receive cetuximab.

Keywords:

Carcinoembryonic antigen
Cetuximab
Immunology
Bevacizumab
Colorectal cancer
Medicine
Oncology
Cancer research
Internal medicine
in patient
first line

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations